论文部分内容阅读
目的:观察生脉注射液联合奥沙利铂(Oxalip latin)应用后瘤重抑制率、免疫功能、肝肾功能以及外周血象的变化。方法:建立H22肝癌荷瘤鼠模型后,随机分为5组,对照组、Oxalip latin组、生脉注射液(大、中、小剂量)+Oxalip latin组,每组10只。造模次日开始进行干预,对照组、Oxalip latin组、生脉注射液(大、中、小剂量)+Oxalip latin组分别予ip等容量5%葡萄糖注射液、Oxalip latin 6 mg/kg、生脉注射液(大14 mL/kg、中7 mL/kg、小3.5 mL/kg剂量)+Oxalip latin 6 mg/kg,用药14 d。停药次日处死,观察瘤重抑制率、免疫功能、肝肾功能、外周血细胞变化。结果:(1)生脉注射液联合Ox-alip latin各组肿瘤生长明显低于Oxalip latin组和对照组(均P<0.05);(2)与对照组相比,Oxalip latin组CD3、CD4、CD4/CD8、IgG、ISM值明显降低(P<0.05),而各生脉联合组CD3、CD4、CD4/CD8、IgG、IgM、IgA值明显升高(P<0.05);(3)与对照组相比,Oxalip latin组ALT升高、WBC降低,而各生脉联合组相对于Oxalip latin组ALT降低、WBC升高(P<0.05)。结论:生脉注射液联合奥沙利铂(Oxalip latin)应用抑瘤效果加强、免疫功能提高,毒副反应减少。
OBJECTIVE: To observe the changes of tumor weight inhibition, immune function, liver and kidney function, and peripheral blood after Shengmai injection combined with Oxalipatin. METHODS: After the H22 tumor bearing mice model was established, they were randomly divided into 5 groups: control group, Oxalip latin group, Shengmai injection (large, medium and small dose) + Oxalip latin group, 10 in each group. The intervention was started the next day after modeling. The control group, Oxalip latin group, Shengmai injection (large, medium, and small dose) + Oxalip latin group were given ip and other volume 5% glucose injection, Oxalip latin 6 mg/kg, raw Pulse injection (large 14 mL/kg, medium 7 mL/kg, small 3.5 mL/kg dose) +Oxalip latin 6 mg/kg for 14 days. The drug was sacrificed the next day and tumor weight inhibition, immune function, liver and kidney function, and changes in peripheral blood cells were observed. Results: (1) The growth of Shengmai injection combined with Ox-alip latin group was significantly lower than that of Oxalip latin group and control group (all P<0.05); (2) Compared with the control group, the Oxalip latin group had CD3, CD4, The CD4/CD8, IgG, and ISM values were significantly lower (P<0.05), and CD3, CD4, CD4/CD8, IgG, IgM, and IgA values were significantly increased in each of the Shengmai combination groups (P<0.05); (3) and the control group. Compared with the group, Oxalip latin group had higher ALT and lower WBC, but each Shengmai combined group had lower ALT and higher WBC than Oxalip latin group (P<0.05). Conclusion: Shengmai injection combined with Oxalip latin has a stronger anti-tumor effect, improved immune function, and fewer side effects.